Profitability ratios measure the company ability to generate profitable sales from its resources (assets).
Paying user area
Try for free
Elevance Health Inc. pages available for free this week:
- Statement of Comprehensive Income
- Balance Sheet: Assets
- Common-Size Income Statement
- Analysis of Solvency Ratios
- Analysis of Short-term (Operating) Activity Ratios
- Analysis of Reportable Segments
- Enterprise Value to EBITDA (EV/EBITDA)
- Selected Financial Data since 2005
- Current Ratio since 2005
- Debt to Equity since 2005
The data is hidden behind: . Unhide it.
Get full access to the entire website from $10.42/mo, or
get 1-month access to Elevance Health Inc. for $24.99.
This is a one-time payment. There is no automatic renewal.
We accept:
Profitability Ratios (Summary)
Based on: 10-Q (reporting date: 2026-06-30), 10-Q (reporting date: 2026-03-31), 10-K (reporting date: 2025-12-31), 10-Q (reporting date: 2025-09-30), 10-Q (reporting date: 2025-06-30), 10-Q (reporting date: 2025-03-31), 10-K (reporting date: 2024-12-31), 10-Q (reporting date: 2024-09-30), 10-Q (reporting date: 2024-06-30), 10-Q (reporting date: 2024-03-31), 10-K (reporting date: 2023-12-31), 10-Q (reporting date: 2023-09-30), 10-Q (reporting date: 2023-06-30), 10-Q (reporting date: 2023-03-31), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-09-30), 10-Q (reporting date: 2022-06-30), 10-Q (reporting date: 2022-03-31).
The profitability profile demonstrates a period of relative stability from early 2022 through mid-2024, followed by a consistent and systemic decline across all measured margins and return ratios through June 2026.
- Profit Margin Analysis
- Gross profit margins remained remarkably stable, fluctuating within a narrow band between 16.79% and 17.16% until June 2024. A trend of contraction emerged in the latter half of 2024, with the margin sliding to 14.10% by June 2026. This erosion is mirrored in the operating and net profit margins, though the decline is more pronounced in relative terms. The operating profit margin, which hovered around 5% for much of 2022, experienced a steady deterioration, ending the period at 2.47%. Similarly, the net profit margin declined from a high of 4.37% in March 2022 to 2.50% by June 2026, indicating a compression of bottom-line profitability.
- Returns on Capital and Assets
- Return on Equity (ROE) and Return on Assets (ROA) both exhibit a clear downward trajectory. ROE maintained a range of 16% to 17% through mid-2023 but began a sustained descent thereafter, falling to 11.06% by June 2026. ROA followed a similar pattern, decreasing from an initial 6.21% to 3.93% over the observed timeline. The synchronized decline in both ROE and ROA suggests a reduction in the efficiency with which assets and shareholder equity are being utilized to generate profit.
- Comparative Trend Observations
- The data reveals a transition from a high-efficiency phase to a period of declining margins. While the gross margin contraction is significant, the more aggressive drop in operating profit margins suggests that operating expenses may be increasing at a faster rate than the cost of goods sold. The overall trend indicates a progressive weakening of profitability across every tracked metric starting in late 2023 and accelerating through 2025 and 2026.
Return on Sales
Return on Investment
Gross Profit Margin
| Jun 30, 2026 | Mar 31, 2026 | Dec 31, 2025 | Sep 30, 2025 | Jun 30, 2025 | Mar 31, 2025 | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | |||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Selected Financial Data (US$ in millions) | ||||||||||||||||||||||||
| Gross profit | ||||||||||||||||||||||||
| Operating revenue | ||||||||||||||||||||||||
| Profitability Ratio | ||||||||||||||||||||||||
| Gross profit margin1 | ||||||||||||||||||||||||
| Benchmarks | ||||||||||||||||||||||||
| Gross Profit Margin, Competitors2 | ||||||||||||||||||||||||
| Abbott Laboratories | ||||||||||||||||||||||||
| Intuitive Surgical Inc. | ||||||||||||||||||||||||
| Medtronic PLC | ||||||||||||||||||||||||
| UnitedHealth Group Inc. | ||||||||||||||||||||||||
Based on: 10-Q (reporting date: 2026-06-30), 10-Q (reporting date: 2026-03-31), 10-K (reporting date: 2025-12-31), 10-Q (reporting date: 2025-09-30), 10-Q (reporting date: 2025-06-30), 10-Q (reporting date: 2025-03-31), 10-K (reporting date: 2024-12-31), 10-Q (reporting date: 2024-09-30), 10-Q (reporting date: 2024-06-30), 10-Q (reporting date: 2024-03-31), 10-K (reporting date: 2023-12-31), 10-Q (reporting date: 2023-09-30), 10-Q (reporting date: 2023-06-30), 10-Q (reporting date: 2023-03-31), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-09-30), 10-Q (reporting date: 2022-06-30), 10-Q (reporting date: 2022-03-31).
1 Q2 2026 Calculation
Gross profit margin = 100
× (Gross profitQ2 2026
+ Gross profitQ1 2026
+ Gross profitQ4 2025
+ Gross profitQ3 2025)
÷ (Operating revenueQ2 2026
+ Operating revenueQ1 2026
+ Operating revenueQ4 2025
+ Operating revenueQ3 2025)
= 100 × ( + + + )
÷ ( + + + )
=
2 Click competitor name to see calculations.
A comprehensive evaluation of the profitability metrics reveals a divergence between revenue growth and gross profit efficiency. While operating revenue demonstrates a consistent upward trajectory over the analyzed period, the gross profit margin exhibits a transition from stability to a sustained decline.
- Revenue Growth Trends
- Operating revenue increased steadily from 37,886 million USD in March 2022 to 49,826 million USD by June 2026. This growth indicates a significant expansion in the scale of operations, with revenue increasing by approximately 31.5% over the recorded timeframe.
- Gross Profit Margin Stability (March 2022 – June 2024)
- For the first two years of the period, the gross profit margin remained remarkably stable, fluctuating within a narrow band between 16.79% and 17.16%. During this phase, gross profit growth largely mirrored revenue growth, suggesting a controlled cost of sales relative to income.
- Margin Contraction and Erosion (September 2024 – June 2026)
- A distinct downward trend in the gross profit margin began in September 2024, falling from 16.62% to 14.10% by June 2026. This erosion occurs despite the continued increase in operating revenue, signifying that the cost of delivering services grew at a faster rate than the revenue generated.
- Profitability Correlation
- The data indicates a decoupling of revenue and gross profit. In the latter half of the analysis, the peak gross profit values achieved in the first quarters of each year are progressively lower relative to the corresponding revenue peaks. This trend confirms a systemic reduction in the percentage of revenue retained as gross profit.
Operating Profit Margin
| Jun 30, 2026 | Mar 31, 2026 | Dec 31, 2025 | Sep 30, 2025 | Jun 30, 2025 | Mar 31, 2025 | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | |||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Selected Financial Data (US$ in millions) | ||||||||||||||||||||||||
| Operating income | ||||||||||||||||||||||||
| Operating revenue | ||||||||||||||||||||||||
| Profitability Ratio | ||||||||||||||||||||||||
| Operating profit margin1 | ||||||||||||||||||||||||
| Benchmarks | ||||||||||||||||||||||||
| Operating Profit Margin, Competitors2 | ||||||||||||||||||||||||
| Abbott Laboratories | ||||||||||||||||||||||||
| Intuitive Surgical Inc. | ||||||||||||||||||||||||
| Medtronic PLC | ||||||||||||||||||||||||
| UnitedHealth Group Inc. | ||||||||||||||||||||||||
Based on: 10-Q (reporting date: 2026-06-30), 10-Q (reporting date: 2026-03-31), 10-K (reporting date: 2025-12-31), 10-Q (reporting date: 2025-09-30), 10-Q (reporting date: 2025-06-30), 10-Q (reporting date: 2025-03-31), 10-K (reporting date: 2024-12-31), 10-Q (reporting date: 2024-09-30), 10-Q (reporting date: 2024-06-30), 10-Q (reporting date: 2024-03-31), 10-K (reporting date: 2023-12-31), 10-Q (reporting date: 2023-09-30), 10-Q (reporting date: 2023-06-30), 10-Q (reporting date: 2023-03-31), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-09-30), 10-Q (reporting date: 2022-06-30), 10-Q (reporting date: 2022-03-31).
1 Q2 2026 Calculation
Operating profit margin = 100
× (Operating incomeQ2 2026
+ Operating incomeQ1 2026
+ Operating incomeQ4 2025
+ Operating incomeQ3 2025)
÷ (Operating revenueQ2 2026
+ Operating revenueQ1 2026
+ Operating revenueQ4 2025
+ Operating revenueQ3 2025)
= 100 × ( + + + )
÷ ( + + + )
=
2 Click competitor name to see calculations.
An analysis of the operational performance reveals a widening divergence between revenue growth and operating profitability. While the top-line revenue exhibited consistent expansion, the efficiency of converting that revenue into operating profit declined steadily over the analyzed period.
- Revenue Trajectory
- Operating revenue demonstrated a sustained upward trend, increasing from 37,886 million US dollars in March 2022 to 49,826 million US dollars by June 2026. This indicates a continuous expansion of the scale of operations.
- Operating Income Volatility and Seasonality
- Operating income is characterized by significant cyclical fluctuations. A recurring pattern is observed where profitability reaches a peak in the first quarter (March) and bottoms out in the fourth quarter (December) of each year. The severity of these year-end contractions increased over time, with December 2025 recording a low of 145 million US dollars, compared to 1,121 million US dollars in December 2022.
- Operating Profit Margin Erosion
- The operating profit margin shows a systemic downward trend, falling from 5.10% in March 2022 to 2.47% by June 2026. Although the margin remained relatively stable around 5% through 2022, a more aggressive decline began in 2023. The acceleration of this trend is most evident between March 2025 (4.07%) and June 2026 (2.47%), suggesting that operating costs scaled more rapidly than revenue growth during the latter half of the period.
Net Profit Margin
| Jun 30, 2026 | Mar 31, 2026 | Dec 31, 2025 | Sep 30, 2025 | Jun 30, 2025 | Mar 31, 2025 | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | |||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Selected Financial Data (US$ in millions) | ||||||||||||||||||||||||
| Shareholders’ net income | ||||||||||||||||||||||||
| Operating revenue | ||||||||||||||||||||||||
| Profitability Ratio | ||||||||||||||||||||||||
| Net profit margin1 | ||||||||||||||||||||||||
| Benchmarks | ||||||||||||||||||||||||
| Net Profit Margin, Competitors2 | ||||||||||||||||||||||||
| Abbott Laboratories | ||||||||||||||||||||||||
| Intuitive Surgical Inc. | ||||||||||||||||||||||||
| Medtronic PLC | ||||||||||||||||||||||||
| UnitedHealth Group Inc. | ||||||||||||||||||||||||
Based on: 10-Q (reporting date: 2026-06-30), 10-Q (reporting date: 2026-03-31), 10-K (reporting date: 2025-12-31), 10-Q (reporting date: 2025-09-30), 10-Q (reporting date: 2025-06-30), 10-Q (reporting date: 2025-03-31), 10-K (reporting date: 2024-12-31), 10-Q (reporting date: 2024-09-30), 10-Q (reporting date: 2024-06-30), 10-Q (reporting date: 2024-03-31), 10-K (reporting date: 2023-12-31), 10-Q (reporting date: 2023-09-30), 10-Q (reporting date: 2023-06-30), 10-Q (reporting date: 2023-03-31), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-09-30), 10-Q (reporting date: 2022-06-30), 10-Q (reporting date: 2022-03-31).
1 Q2 2026 Calculation
Net profit margin = 100
× (Shareholders’ net incomeQ2 2026
+ Shareholders’ net incomeQ1 2026
+ Shareholders’ net incomeQ4 2025
+ Shareholders’ net incomeQ3 2025)
÷ (Operating revenueQ2 2026
+ Operating revenueQ1 2026
+ Operating revenueQ4 2025
+ Operating revenueQ3 2025)
= 100 × ( + + + )
÷ ( + + + )
=
2 Click competitor name to see calculations.
The financial performance from March 2022 through June 2026 is characterized by a divergence between top-line growth and bottom-line efficiency. While operating revenue has maintained a consistent upward trajectory, the net profit margin has experienced a steady long-term decline, indicating a compression in profitability despite an expanding scale of operations.
- Operating Revenue Trends
- A sustained increase in operating revenue is observed, rising from 37,886 million USD in March 2022 to 49,826 million USD by June 2026. This represents a significant expansion in the volume of business activities over the analyzed period.
- Net Profit Margin Erosion
- The net profit margin exhibits a clear downward trend, starting at 4.37% in March 2022 and falling to 2.50% by June 2026. This decline suggests that operating expenses or other costs have grown at a faster rate than revenue, eroding the percentage of each dollar of revenue that translates into actual profit.
- Net Income Volatility and Seasonality
- Shareholders' net income demonstrates significant quarterly fluctuations with a recurring seasonal pattern. Substantial troughs are consistently recorded in the fourth quarter of each year, specifically in December 2022 (949 million USD), December 2023 (856 million USD), December 2024 (418 million USD), and December 2025 (547 million USD). Conversely, the first quarter of each year typically shows the strongest net income recovery.
- Correlation Between Scale and Profitability
- Despite the growth in revenue, the inability to maintain net income levels relative to that growth is evident. The lowest recorded net profit margin of 2.50% occurs at the point of highest operating revenue in June 2026, confirming a negative correlation between the increase in operational scale and the net profit margin during this timeframe.
Return on Equity (ROE)
| Jun 30, 2026 | Mar 31, 2026 | Dec 31, 2025 | Sep 30, 2025 | Jun 30, 2025 | Mar 31, 2025 | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | |||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Selected Financial Data (US$ in millions) | ||||||||||||||||||||||||
| Shareholders’ net income | ||||||||||||||||||||||||
| Shareholders’ equity | ||||||||||||||||||||||||
| Profitability Ratio | ||||||||||||||||||||||||
| ROE1 | ||||||||||||||||||||||||
| Benchmarks | ||||||||||||||||||||||||
| ROE, Competitors2 | ||||||||||||||||||||||||
| Abbott Laboratories | ||||||||||||||||||||||||
| Intuitive Surgical Inc. | ||||||||||||||||||||||||
| Medtronic PLC | ||||||||||||||||||||||||
| UnitedHealth Group Inc. | ||||||||||||||||||||||||
Based on: 10-Q (reporting date: 2026-06-30), 10-Q (reporting date: 2026-03-31), 10-K (reporting date: 2025-12-31), 10-Q (reporting date: 2025-09-30), 10-Q (reporting date: 2025-06-30), 10-Q (reporting date: 2025-03-31), 10-K (reporting date: 2024-12-31), 10-Q (reporting date: 2024-09-30), 10-Q (reporting date: 2024-06-30), 10-Q (reporting date: 2024-03-31), 10-K (reporting date: 2023-12-31), 10-Q (reporting date: 2023-09-30), 10-Q (reporting date: 2023-06-30), 10-Q (reporting date: 2023-03-31), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-09-30), 10-Q (reporting date: 2022-06-30), 10-Q (reporting date: 2022-03-31).
1 Q2 2026 Calculation
ROE = 100
× (Shareholders’ net incomeQ2 2026
+ Shareholders’ net incomeQ1 2026
+ Shareholders’ net incomeQ4 2025
+ Shareholders’ net incomeQ3 2025)
÷ Shareholders’ equity
= 100 × ( + + + )
÷ =
2 Click competitor name to see calculations.
The analysis of the profitability metrics reveals a consistent long-term decline in Return on Equity (ROE) despite a general increase in the total equity base. The ROE transitioned from a peak of 17.36% in March 2022 to a period low of 11.06% by June 2026, indicating a reduction in the efficiency of generating profits from shareholders' investments.
- Return on Equity Trend
- A sustained downward trajectory is observed in the ROE over the analyzed period. The ratio remained relatively stable throughout 2022, fluctuating between 16.59% and 17.36%. However, beginning in 2023, a gradual erosion occurred, with the ROE falling below 15% in late 2024 and continuing a steady decline through the first half of 2026.
- Equity Base Expansion
- Shareholders' equity demonstrated a steady growth pattern, increasing from 35,975 million US dollars in March 2022 to 44,883 million US dollars by June 2026. This expansion represents a significant increase in the capital base. Because the equity denominator grew more consistently than the corresponding net income, a mathematical compression of the ROE was inevitable.
- Net Income Volatility and Seasonality
- Shareholders' net income exhibits pronounced quarterly seasonality, characterized by peaks in the first and second quarters and significant troughs in the fourth quarter of each year. While certain peaks showed strength—such as the 2,300 million US dollars recorded in June 2024—the fourth-quarter results showed a concerning downward trend, dropping from 949 million US dollars in December 2022 to 547 million US dollars in December 2025. This volatility, paired with the expanding equity base, has accelerated the decline in overall profitability efficiency.
Return on Assets (ROA)
| Jun 30, 2026 | Mar 31, 2026 | Dec 31, 2025 | Sep 30, 2025 | Jun 30, 2025 | Mar 31, 2025 | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | |||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Selected Financial Data (US$ in millions) | ||||||||||||||||||||||||
| Shareholders’ net income | ||||||||||||||||||||||||
| Total assets | ||||||||||||||||||||||||
| Profitability Ratio | ||||||||||||||||||||||||
| ROA1 | ||||||||||||||||||||||||
| Benchmarks | ||||||||||||||||||||||||
| ROA, Competitors2 | ||||||||||||||||||||||||
| Abbott Laboratories | ||||||||||||||||||||||||
| Intuitive Surgical Inc. | ||||||||||||||||||||||||
| Medtronic PLC | ||||||||||||||||||||||||
| UnitedHealth Group Inc. | ||||||||||||||||||||||||
Based on: 10-Q (reporting date: 2026-06-30), 10-Q (reporting date: 2026-03-31), 10-K (reporting date: 2025-12-31), 10-Q (reporting date: 2025-09-30), 10-Q (reporting date: 2025-06-30), 10-Q (reporting date: 2025-03-31), 10-K (reporting date: 2024-12-31), 10-Q (reporting date: 2024-09-30), 10-Q (reporting date: 2024-06-30), 10-Q (reporting date: 2024-03-31), 10-K (reporting date: 2023-12-31), 10-Q (reporting date: 2023-09-30), 10-Q (reporting date: 2023-06-30), 10-Q (reporting date: 2023-03-31), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-09-30), 10-Q (reporting date: 2022-06-30), 10-Q (reporting date: 2022-03-31).
1 Q2 2026 Calculation
ROA = 100
× (Shareholders’ net incomeQ2 2026
+ Shareholders’ net incomeQ1 2026
+ Shareholders’ net incomeQ4 2025
+ Shareholders’ net incomeQ3 2025)
÷ Total assets
= 100 × ( + + + )
÷ =
2 Click competitor name to see calculations.
An analysis of the financial performance from March 31, 2022, to June 30, 2026, reveals a consistent decline in asset utilization efficiency. While the balance sheet has expanded steadily, net income has not grown at a commensurate rate, resulting in a sustained downward trajectory for the Return on Assets (ROA).
- Asset Base Expansion
- Total assets exhibited a steady upward trend throughout the period, increasing from 100,486 million US dollars in March 2022 to 126,438 million US dollars by June 2026. This represents a continuous growth in the company's resource base, with significant increases particularly observed between March 2024 and March 2026.
- Net Income Volatility
- Shareholders’ net income demonstrated significant quarterly fluctuations. A recurring seasonal pattern is evident, typically peaking in the first quarter of each year and reaching troughs in the fourth quarter. Despite these periodic spikes, such as the 2,300 million US dollars reported in June 2024, the earnings levels failed to scale proportionally with the expanding asset base.
- Return on Assets (ROA) Trend
- The ROA experienced a persistent decline over the analyzed timeframe, falling from a high of 6.21% in March 2022 to 3.93% by June 2026. The decline was gradual through 2022 and 2023, remaining largely between 5.50% and 6.00%. However, a more pronounced deterioration began in 2024, with the ratio dropping below 5.00% by March 2025 and continuing to fall through the first half of 2026.
The convergence of increasing total assets and stagnant or volatile net income has led to a compression of the ROA. This suggests a diminishing ability to generate profit from each dollar of assets held, indicating a reduction in overall operational efficiency over the five-year period.